Robert Q. Le
Impact in
- Oncology top 10%
- CAR-T cell therapy research
- Hematology top 10%
- Hematopoietic Stem Cell Transplantation
Papers in
- Hematology 10
- Hematopoietic Stem Cell Transplantation 7
- Acute Myeloid Leukemia Research 6
- Chronic Myeloid Leukemia Treatments 2
- Oncology 7
- CAR-T cell therapy research 5
- Co-authors
- Donna Przepiorka (5 shared papers)Richard Pazdur (3 shared papers)Weishi Yuan (2 shared papers)Stacy S. Shord (2 shared papers)Bahru Habtemariam (2 shared papers)Lei Nie (1 shared paper)Liang Li (2 shared papers)Ann T. Farrell (2 shared papers)
- Journals
- Blood (4 papers)Biology of Blood and Marrow Transplantation (3 papers)The Oncologist (2 papers)Clinical Cancer Research (1 paper)Cancer Immunology Immunotherapy (1 paper)
- Partner nations
- United StatesGermanyCanada
In The Last Decade
Robert Q. Le
15 papers receiving 740 citations
Robert Q. Le's Hit Papers
Peers
Comparison fields: 5 of 80
- Oncology 397
- Hematology 131
- Infectious Diseases 216
- Neurology 163
- Immunology 162
Countries citing papers authored by Robert Q. Le
This map shows the geographic impact of Robert Q. Le's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Q. Le with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Q. Le more than expected).
Fields of papers citing papers by Robert Q. Le
This network shows the impact of papers produced by Robert Q. Le. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Q. Le. The network helps show where Robert Q. Le may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert Q. Le, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome Hit paper breakdown → | 2018 | 610 |
| 2 | 2016 | 29 | |
| 3 | 2010 | 24 | |
| 4 | 2022 | 17 | |
| 5 | 2013 | 15 | |
| 6 | 2011 | 13 | |
| 7 | 2011 | 12 | |
| 8 | 2017 | 9 | |
| 9 | 2018 | 7 | |
| 10 | 2024 | 6 | |
| 11 | 2015 | 5 | |
| 12 | 2020 | 4 | |
| 13 | 2018 | 2 | |
| 14 | 2014 | 1 | |
| 15 | 2013 | 1 | |
| 16 | 2025 | 0 |
About Robert Q. Le
Robert Q. Le is a scholar working on Hematology, Oncology, Immunology, Cardiology and Cardiovascular Medicine and Public Health, Environmental and Occupational Health, having authored 16 papers that have together received 755 indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (7 papers), Acute Myeloid Leukemia Research (6 papers), CAR-T cell therapy research (5 papers), Chronic Myeloid Leukemia Treatments (2 papers), Acute Lymphoblastic Leukemia research (2 papers), T-cell and B-cell Immunology (2 papers), Chemotherapy-induced cardiotoxicity and mitigation (2 papers) and Mobile Health and mHealth Applications (1 paper). The work is most often cited by research in Oncology (397 citations), Hematology (131 citations), Infectious Diseases (216 citations), Neurology (163 citations) and Immunology (162 citations). Robert Q. Le has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Donna Przepiorka, Richard Pazdur, Weishi Yuan, Stacy S. Shord, Bahru Habtemariam, Lei Nie, Liang Li, Ann T. Farrell, Bipin N. Savani and A. John Barrett. Their work appears in journals such as Blood, Biology of Blood and Marrow Transplantation, The Oncologist, Clinical Cancer Research and Cancer Immunology Immunotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.